Evaluation of FGFR2 gene polymorphism in women with breast cancer

Breast cancer (BC) is one of the most frequent cancers among women worldwide. It is a complex polygenic disorder that genetic factors play an important role in disease etiology. The highly significant association of the Fibroblast growth factor receptor 2 (FGFR2) locus with breast cancer risk has been replicated in multiple genome association study; however, it's mechanism of action remains unclear. The aim of this study was to investigate whether the single nucleotide polymorphism (SNP) C—906T within intron 2 of FGFR2 is responsible for susceptibility to breast cancer. This case-control study included 108 breast cancer cases and 108 cancer-free controls. The prevalence of genotype frequencies of the FGFR2 CC/CT/TT was 5.5%, 90.7% and 3.7%, respectively, in cancer cases. Among controls, the distribution of CC, CT and TT genotype was 48.14%, 47.66% and 10.18% respectively. Significant differences in allele and genotype distribution among controls and patients were found (OR, 18.87 95% CI, 7.55—47.16; p = 0.0001). The results from this study suggest that the FGFR2 C—906T polymorphism may be associated to breast cancer in population studied. Well—designed studies with larger sample sizes are needed to confirm the role of FGFR2 SNP in breast cancer risk.